[go: up one dir, main page]

MX2010014228A - Metodos y productos de diagnostico del p/gf-1 acompañante. - Google Patents

Metodos y productos de diagnostico del p/gf-1 acompañante.

Info

Publication number
MX2010014228A
MX2010014228A MX2010014228A MX2010014228A MX2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A
Authority
MX
Mexico
Prior art keywords
methods
accompanying
drug
treatment
diagnosis
Prior art date
Application number
MX2010014228A
Other languages
English (en)
Inventor
D Tyner Joan
C Sogin David
N Ziemann Robert
Datwyler Saul
J Hawksworth David
M Laird Don
L Pucci Dominick
R Lesniewski Richard
Mary McKeegan Evelyn
Original Assignee
Abbott Laboratories Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/485,114 external-priority patent/US8741287B2/en
Application filed by Abbott Laboratories Star filed Critical Abbott Laboratories Star
Publication of MX2010014228A publication Critical patent/MX2010014228A/es

Links

Classifications

    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a, entre otras cosas, métodos para determinar si un sujeto que está recibiendo tratamiento con un fármaco ha obtenido un nivel eficaz, en sangre, del fármaco. Además, la presente descripción también se refiere a métodos para determinar si un sujeto predispuesto a o que sufre de una enfermedad se beneficiará del tratamiento con un fármaco, y la respuesta de un sujeto que recibe un tratamiento (por ejemplo, tal como para cáncer) verificando los biomarcadores de angiogénesis. En particular, la descripción se refiere a métodos y productor de diagnóstico del p/GF-1 acompañante.
MX2010014228A 2008-06-18 2009-06-17 Metodos y productos de diagnostico del p/gf-1 acompañante. MX2010014228A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7362408P 2008-06-18 2008-06-18
US8917208P 2008-08-15 2008-08-15
US11006308P 2008-10-31 2008-10-31
US12/485,114 US8741287B2 (en) 2008-06-18 2009-06-16 PlGF-1 assay and kits and components thereof
PCT/US2009/047714 WO2009155381A1 (en) 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products

Publications (1)

Publication Number Publication Date
MX2010014228A true MX2010014228A (es) 2011-03-29

Family

ID=41434433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014228A MX2010014228A (es) 2008-06-18 2009-06-17 Metodos y productos de diagnostico del p/gf-1 acompañante.

Country Status (6)

Country Link
EP (1) EP2300825A4 (es)
JP (1) JP2011525241A (es)
CN (1) CN102224419A (es)
CA (1) CA2728449A1 (es)
MX (1) MX2010014228A (es)
WO (1) WO2009155381A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2011107259A1 (en) * 2010-03-05 2011-09-09 Ophthalmopharma Ag Nutraceutical chocolate or compound chocolate product
HRP20191713T1 (hr) 2011-07-01 2019-12-27 Ngm Biopharmaceuticals, Inc. Pripravci, uporabe i metode za liječenje metaboličkih poremećaja i bolesti
UY34812A (es) * 2012-05-18 2013-12-31 Teva Pharma Método para el tratamiento del cáncer de pulmón de células no pequeñas
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
SG10202100667SA (en) 2012-12-27 2021-02-25 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EA037406B1 (ru) * 2016-01-25 2021-03-25 Санофи Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2022099465A1 (zh) * 2020-11-10 2022-05-19 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
ATE493652T1 (de) * 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics Quantitative assays für pdgfr-beta- in körperflüssigkeiten
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
AU2006312058A1 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2029743A4 (en) * 2006-05-31 2010-12-08 Beth Israel Hospital METHODS FOR DIAGNOSING AND TREATING COMPLICATIONS ASSOCIATED WITH PREGNANCY
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CN102224419A (zh) 2011-10-19
CA2728449A1 (en) 2009-12-23
EP2300825A4 (en) 2012-04-25
WO2009155381A1 (en) 2009-12-23
EP2300825A1 (en) 2011-03-30
JP2011525241A (ja) 2011-09-15

Similar Documents

Publication Publication Date Title
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
Ghorbani et al. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
MX2014015236A (es) Elemento de compresion de seno opticamente adaptable.
MX2010007822A (es) Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
MX361731B (es) Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk.
TN2014000454A1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
AR081696A1 (es) Anticuerpo para el diagnostico y/o pronostico de cancer
AR088244A1 (es) oxMIF COMO MARCADOR DE DIAGNOSTICO
CY1123265T1 (el) Μια αναλυση κυτταρικως μεσολαβουμενης ανοσοαποκρισhς
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
BR112015014232A2 (pt) lesão renal aguda
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata
BR112012007557A2 (pt) alterações anormais de processamento de isozimas de pkc em células periféricas da doença de alzheimer
PE20141723A1 (es) Metodo para monitoreo, diagnostico y/o pronostico de trastornos relacionados con hipoxia utilizando nfat5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal